EP0099297A1 - Cephalosporinderivate, Verfahren zu ihrer Herstellung und sie enthaltende antibiotische Medikamente - Google Patents

Cephalosporinderivate, Verfahren zu ihrer Herstellung und sie enthaltende antibiotische Medikamente Download PDF

Info

Publication number
EP0099297A1
EP0099297A1 EP83401413A EP83401413A EP0099297A1 EP 0099297 A1 EP0099297 A1 EP 0099297A1 EP 83401413 A EP83401413 A EP 83401413A EP 83401413 A EP83401413 A EP 83401413A EP 0099297 A1 EP0099297 A1 EP 0099297A1
Authority
EP
European Patent Office
Prior art keywords
group
acid
formula
ppm
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP83401413A
Other languages
English (en)
French (fr)
Other versions
EP0099297B1 (de
Inventor
Bernard Labeeuw
Ali Salhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to AT83401413T priority Critical patent/ATE33392T1/de
Publication of EP0099297A1 publication Critical patent/EP0099297A1/de
Application granted granted Critical
Publication of EP0099297B1 publication Critical patent/EP0099297B1/de
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36Methylene radicals, substituted by sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Definitions

  • the present invention relates to derivatives of the cephalosporin family, their preparation process and their therapeutic application.
  • the double bond of the isothiouronium function can be localized as shown in the formula for compound (1).
  • the compounds (1) exist in two syn and anti isomeric forms.
  • the syn isomers with higher therapeutic activity are the preferred compounds.
  • the invention also relates to a process for the preparation of the compounds of formula (I).
  • This process consists in first of all acycling the 7-amino-3-bromomethyl-3 cephem-3-tert-butyl carboxylate S-oxide (II) by the acid (III) according to the following reaction scheme in which R ' l represents l 't-butyl ester corresponding to R 1 .
  • the groups usually used in organic synthesis can be used for the protection of amino groups and, in particular, the trityl group.
  • the substituent R of acid (III) contains a carboxylic group
  • an ester that is sufficiently labile is chosen to be able to regenerate the acid function at the end of the reaction. Most commonly used is the tert-butyl ester.
  • the activation reaction is carried out in a suitable organic solvent such as tetrahydrofuran at a temperature between 0 and 50 ° C and, preferably, at room temperature.
  • a suitable organic solvent such as tetrahydrofuran
  • the activation reaction is optionally facilitated by adding a hydroxylated derivative such as 1-hydroxybenzotriazole.
  • the solution of acylation reagent thus obtained, freed by filtration of the dicyclohexylurea formed, is added to a solution of compound (II) in a solvent such as dimethylformamide.
  • a solvent such as dimethylformamide.
  • the acylation can also be carried out with the acid chloride of (III):
  • the operation is carried out in a suitable solvent such as dimethylformamide or N, N-dimethylacetamide in the presence of a base such as triethylamine.
  • a suitable solvent such as dimethylformamide or N, N-dimethylacetamide
  • a base such as triethylamine.
  • the protective group on the amine and the tert-butyl ester group (s) are eliminated by a known process, in particular by hydrolysis in an acid medium using an organic acid such as formic acid or trifluoroacetic acid or a hydrochloric acid - acetic acid mixture.
  • R 2 , R 3 , R 45 R 5 represent alkyl or alkenyl groups are prepared according to the methods described in: EH RODD, Chemistry of Aliphatic compounds, vol. IB. Elsevier, 1952, 924-929.
  • the thioureas in which R 4 and R 5 taken together with the nitrogen atom to which they are bonded form a 5- or 6-membered ring nucleus are prepared from dimethylthio-carbamoyl chloride or methyl isothiocyanate on which reacts the nitrogen heterocycle according to the reaction scheme below:
  • the mineral salts are obtained by action on the compounds (I) in which A is H of a mineral base such as soda or potash or sodium bicarbonate in equimolecular amount; the salification reaction is carried out in a solvent such as water or ethanol and the salt obtained is isolated by evaporation of the solution.
  • A is H of a mineral base such as soda or potash or sodium bicarbonate in equimolecular amount; the salification reaction is carried out in a solvent such as water or ethanol and the salt obtained is isolated by evaporation of the solution.
  • the salt is isolated by precipitation with ether.
  • esters are obtained by known methods of esterification; for example, advantageously use the action of a halogenated derivative on a salt such as the sodium salt of the acid; the reaction will preferably be carried out in a solvent capable of dissolving the starting acid derivative, for example in dimethylformamide.
  • the syn and anti isomers are obtained by a suitable choice of reagents or experimental conditions.
  • the products according to the invention do not have a clear melting point, but only decomposition points which do not allow them to be characterized.
  • the products will therefore be characterized by their nuclear magnetic resonance spectrum recorded at 60 MHz or 250 MHz, the internal standard being hexamethyldisiloxane.
  • the spectra are recorded in deuterium dimethyl sulfoxide.
  • a suspension of 20 g of (2-tritylamino-thia-zolyl-4) -2 (t-butoxy-carbonyl-2-propyl-2-oxyimino) -2 acetic acid in 100 ml of methylene chloride cooled to 0 ° - 2 is prepared. ° C. 7.3 g of PCl 5 are added slowly and the mixture is stirred for 30 minutes at this temperature. I pour I liter of hexane to precipitate then filter and dry under vacuum to obtain 21.2 g of acid chloride (2-tritylamino-thiazolyl-4) -2 (t-butoxycarbonyl-2-propyl-2 oxyimino) -2 acetic. Melting point: 135 ° C.
  • the solid obtained is redissolved in 5 ml of methylene chloride and then chromatographed on 25 g of silica gel, the eluent is a mixture of methylene chloride-methanol 90/10 (vol / vol).
  • This product is prepared in the same way and under the same operating conditions as CM 41 089, starting from (2-tritylamino-thiazolyl-4) -2 (t-butoxycarbonyl-1 ethyl-1 oxyimino) -2 acetic acid .
  • SR 41 361 A a mixture of 2 diastereoisomers, is identified by its spectrum.
  • the products of the invention can therefore be used as antibiotics in human or veterinary medicine. They can be used in all bacterial infections with susceptible germs.
  • the products of the invention have been studied as regards their pharmacological properties and, more particularly, the bacteriostatic action.
  • the bacteriostatic action in vitro was determined in solid medium by the dilution method.
  • the results expressed in minimum inhibitory concentrations relate to the results obtained on different strains.
  • compositions are produced from the compounds (I) in their acid form or, when their solubility is insufficient, in the form of a salt.
  • compositions can be solid or liquid and can be presented, for example, in the form of tablets, capsules, granules, ointments, creams, gels or injectable preparations.
  • the dosage can vary within wide limits, in particular according to the type and severity of the infection to be treated and according to the mode of administration. Most often, in adults by injection, it is between 0.250 g and 4 g per day.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP83401413A 1982-07-13 1983-07-08 Cephalosporinderivate, Verfahren zu ihrer Herstellung und sie enthaltende antibiotische Medikamente Expired EP0099297B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT83401413T ATE33392T1 (de) 1982-07-13 1983-07-08 Cephalosporinderivate, verfahren zu ihrer herstellung und sie enthaltende antibiotische medikamente.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8212317A FR2530248A1 (fr) 1982-07-13 1982-07-13 Nouveaux derives des cephalosporines, leur procede de preparation et medicaments antibiotiques contenant lesdits derives
FR8212317 1982-07-13

Publications (2)

Publication Number Publication Date
EP0099297A1 true EP0099297A1 (de) 1984-01-25
EP0099297B1 EP0099297B1 (de) 1988-04-06

Family

ID=9275967

Family Applications (1)

Application Number Title Priority Date Filing Date
EP83401413A Expired EP0099297B1 (de) 1982-07-13 1983-07-08 Cephalosporinderivate, Verfahren zu ihrer Herstellung und sie enthaltende antibiotische Medikamente

Country Status (28)

Country Link
US (1) US4578377A (de)
EP (1) EP0099297B1 (de)
JP (1) JPS5973590A (de)
KR (1) KR840005455A (de)
AT (1) ATE33392T1 (de)
AU (1) AU555185B2 (de)
CA (1) CA1209126A (de)
CS (1) CS236797B2 (de)
DD (1) DD210054A5 (de)
DE (1) DE3376213D1 (de)
DK (1) DK323183A (de)
EG (1) EG15964A (de)
ES (1) ES8405412A1 (de)
FI (1) FI74286C (de)
FR (1) FR2530248A1 (de)
GR (1) GR79285B (de)
HU (1) HU189712B (de)
IL (1) IL69210A (de)
MA (1) MA19841A1 (de)
NO (1) NO832515L (de)
NZ (1) NZ204873A (de)
OA (1) OA07495A (de)
PH (1) PH19298A (de)
PL (1) PL141582B1 (de)
PT (1) PT77017B (de)
SU (1) SU1194280A3 (de)
YU (1) YU149683A (de)
ZA (1) ZA835101B (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678781A (en) * 1983-06-03 1987-07-07 Ici Pharma 3-substituted-aminomethyl cephalosporin derivatives
US4855420A (en) * 1983-06-03 1989-08-08 Ici Pharma Cephalosporin derivatives
US4868173A (en) * 1984-11-20 1989-09-19 Ici Pharma Cephalosporin derivatives
EP0333082A2 (de) * 1988-03-15 1989-09-20 Takeda Chemical Industries, Ltd. Cephemverbindungen, ihre Herstellung und Anwendung
EP0382220A2 (de) * 1989-02-10 1990-08-16 Meiji Seika Kaisha Ltd. Verfahren zur Herstellung von Aminothiazolylessigsäure-Derivate

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053953A1 (en) * 2011-10-14 2013-04-18 Université de Liège Method for measuring beta-lactam antibiotics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2030M (fr) * 1961-05-16 1963-10-25 Glaxo Lab Ltd Médicament anti-bactérien et antibiotique a base de dérivés de la céphalosporine c.
FR2442240A1 (fr) * 1978-11-27 1980-06-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-substitue 7-amino thiazolyl acetamido cephalosporanique comportant un groupement eliminable sur le radical amino, leur procede de preparation et leur application a la synthese de produits actifs comme medicaments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1012943A (en) * 1961-05-16 1965-12-15 Glaxo Lab Ltd Improvements in or relating to antibiotics
DE2716677C2 (de) * 1977-04-15 1985-10-10 Hoechst Ag, 6230 Frankfurt Cephemderivate und Verfahren zu ihrer Herstellung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2030M (fr) * 1961-05-16 1963-10-25 Glaxo Lab Ltd Médicament anti-bactérien et antibiotique a base de dérivés de la céphalosporine c.
FR2442240A1 (fr) * 1978-11-27 1980-06-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-substitue 7-amino thiazolyl acetamido cephalosporanique comportant un groupement eliminable sur le radical amino, leur procede de preparation et leur application a la synthese de produits actifs comme medicaments

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678781A (en) * 1983-06-03 1987-07-07 Ici Pharma 3-substituted-aminomethyl cephalosporin derivatives
US4855420A (en) * 1983-06-03 1989-08-08 Ici Pharma Cephalosporin derivatives
US4868173A (en) * 1984-11-20 1989-09-19 Ici Pharma Cephalosporin derivatives
EP0333082A2 (de) * 1988-03-15 1989-09-20 Takeda Chemical Industries, Ltd. Cephemverbindungen, ihre Herstellung und Anwendung
EP0333082A3 (de) * 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Cephemverbindungen, ihre Herstellung und Anwendung
EP0382220A2 (de) * 1989-02-10 1990-08-16 Meiji Seika Kaisha Ltd. Verfahren zur Herstellung von Aminothiazolylessigsäure-Derivate
EP0382220A3 (de) * 1989-02-10 1991-03-13 Meiji Seika Kaisha Ltd. Verfahren zur Herstellung von Aminothiazolylessigsäure-Derivate

Also Published As

Publication number Publication date
HU189712B (en) 1986-07-28
FI74286B (fi) 1987-09-30
IL69210A (en) 1986-12-31
PL141582B1 (en) 1987-08-31
AU555185B2 (en) 1986-09-18
DE3376213D1 (en) 1988-05-11
GR79285B (de) 1984-10-22
FR2530248A1 (fr) 1984-01-20
PH19298A (en) 1986-03-05
JPS5973590A (ja) 1984-04-25
FI832522L (fi) 1984-01-14
KR840005455A (ko) 1984-11-12
PL242988A1 (en) 1984-08-13
DK323183A (da) 1984-01-14
MA19841A1 (fr) 1984-04-01
DK323183D0 (da) 1983-07-13
CS236797B2 (en) 1985-05-15
FR2530248B1 (de) 1985-02-15
US4578377A (en) 1986-03-25
ATE33392T1 (de) 1988-04-15
ZA835101B (en) 1984-03-28
SU1194280A3 (ru) 1985-11-23
DD210054A5 (de) 1984-05-30
PT77017B (fr) 1986-01-24
CA1209126A (en) 1986-08-05
ES524040A0 (es) 1984-06-16
NO832515L (no) 1984-01-16
AU1679583A (en) 1984-01-19
EP0099297B1 (de) 1988-04-06
OA07495A (fr) 1985-03-31
FI832522A0 (fi) 1983-07-11
ES8405412A1 (es) 1984-06-16
NZ204873A (en) 1985-12-13
FI74286C (fi) 1988-01-11
IL69210A0 (en) 1983-11-30
PT77017A (fr) 1983-08-01
EG15964A (en) 1986-06-30
YU149683A (en) 1985-10-31

Similar Documents

Publication Publication Date Title
EP0036812B1 (de) Cephalosporinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende antibiotische Präparate
EP0088853B1 (de) Derivate von Pyridinium-Thiomethyl-Cephalosporinen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
FR2676443A1 (fr) Nouveaux derives de perhydroisoindole et leur preparation.
EP0060745B1 (de) Antibiotische Cephalosporinverbindungen
FR2512449A1 (fr) Quinoleinium-betaines de cephalosporine et leur application pharmacolique
GB2111482A (en) Azetidine medicaments
EP0178980B1 (de) Cephalsoporinverbindungen, Verfahren zu ihrer Herstellung und ihre antibiotische Verwendung
FR2472574A1 (fr) Derives de cephalosporine et composition pharmaceutique les contenant
CH638221A5 (fr) Oximes derivees de l'acide 3-substitue 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et les compositions pharmaceutiques les renfermant.
EP0099297B1 (de) Cephalosporinderivate, Verfahren zu ihrer Herstellung und sie enthaltende antibiotische Medikamente
EP0080944B1 (de) Cephalosporinderivate substituiert in Position 3 von einer thiomethylheterocyclischen Gruppe, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Verbindungen
EP0044238B1 (de) Cephalosporinsulfoxyd-Verbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
FR2496666A1 (fr) Nouveaux derives de cephalosporine et composition pharmaceutique les contenant
EP0124384A1 (de) Derivate von orthokondensiertem Pyrrol, verwendbar für die Herstellung von Arzneimitteln und Verfahren zu deren Herstellung
CH654297A5 (fr) 2-oxo-azetidines.
CA1140113A (fr) Procede de preparation de nouvelles oximes 0-substituees par un radical comportant un ammonium quatermaire et derivees de l'acide 7-amino thiazolyl acetamido cephalosporanique
JPS6056989A (ja) β−ラクタム抗バクテリア剤
FR2485540A1 (fr) Nouveaux derives antibiotiques des cephalosporines, leur procede de preparation et les medicaments en contenant
EP0269512B1 (de) Cephalosporinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
EP0311521B1 (de) Cephalosporinderivate mit verbesserter Pharmakokinetik, Verfahren zur ihrer Herstellung, sie enthaltende pharmazeutische Präparate und Zwischenverbindung
FR2509726A1 (de)
CA1097340A (fr) Derives de la cephalosporine, leur preparation et les compositions qui les contiennent
EP0005140B1 (de) 4-Deoxy-thiazolo-(5,4-c)rifamycin-Derivate und Verfahren zu deren Herstellung
EP0101386B1 (de) Cephalosporinverbindungen und ihre Herstellung
FR2498189A1 (fr) Nouveaux derives de l'acide cephalosporanique, leur preparation et leur application comme medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19840605

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19880406

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 19880406

Ref country code: AT

Effective date: 19880406

REF Corresponds to:

Ref document number: 33392

Country of ref document: AT

Date of ref document: 19880415

Kind code of ref document: T

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19880430

REF Corresponds to:

Ref document number: 3376213

Country of ref document: DE

Date of ref document: 19880511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19880731

Ref country code: LI

Effective date: 19880731

Ref country code: CH

Effective date: 19880731

Ref country code: BE

Effective date: 19880731

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
GBV Gb: ep patent (uk) treated as always having been void in accordance with gb section 77(7)/1977 [no translation filed]
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19881122

BERE Be: lapsed

Owner name: S.A. SANOFI

Effective date: 19880731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19890331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19890401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST